NIH-Funding

National Cancer Institute Program Project Applications (P01 Clinical Trial Optional)

NIH Funding Announcements - Mon, 10/30/2017 - 12:06
Funding Opportunity PAR-18-290 from the NIH Guide for Grants and Contracts. With this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for investigator-initiated Program Project (P01) applications. The proposed Program may address any of the broad areas of cancer research, including (but not limited to) cancer biology, cancer prevention, cancer diagnosis, cancer treatment, and cancer control. Basic, translational, clinical, and/or population-based studies in all of these research areas are appropriate. Each application submitted in response to this FOA must consist of at least three research projects and an Administrative Core. The projects must share a common central theme, focus, and/or overall objective.
Categories: NIH-Funding

NIDDK Program Projects (P01 Clinical Trial Optional)

NIH Funding Announcements - Mon, 10/30/2017 - 12:03
Funding Opportunity PAR-18-012 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites submission of investigator-initiated program project applications. The proposed programs should address scientific areas relevant to the NIDDK mission including diabetes, selected endocrine and metabolic diseases, obesity, digestive diseases and nutrition, and kidney, urologic and hematologic diseases, as well as new approaches to prevent, treat and cure these diseases, including clinical research. A description of NIDDK scientific program areas can be found at http://www.niddk.nih.gov/about-niddk/research-areas/pages/research-areas.aspx .
Categories: NIH-Funding

Center of Excellence for Research on Complementary and Integrative Health (P01 Clinical Trial Optional)

NIH Funding Announcements - Mon, 10/30/2017 - 11:59
Funding Opportunity PAR-18-113 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages the submission of applications that requires multi-project, synergistic collaboration between outstanding scientists that blends multiple research approaches by multi-disciplinary research teams. This Center of Excellence for Research on Complementary and Integrative Health (CERCIH) program is designed to support three or more highly meritorious projects that can offer significant scientific advantages and "synergy" that could not be achieved by supporting the same projects as individual research grants. Each CERCIH must be focused on questions of high relevance to the mission of NCCIH.
Categories: NIH-Funding

NIBIB Biomedical Technology Resource Centers (P41 Clinical Trials Optional)

NIH Funding Announcements - Mon, 10/30/2017 - 11:55
Funding Opportunity PAR-18-205 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages grant applications for Biomedical Technology Resource Centers (BTRCs). BTRCs are national resource centers for conducting research and development on new technologies that are driven by the needs of basic, translational, and/or clinical researchers. BTRCs also make their technologies available to other investigators, train members of the research community in the use of the technologies, and disseminate the technologies broadly.
Categories: NIH-Funding

By: Charm3

WriteEdit-Grant Questions Blog - Mon, 10/30/2017 - 11:49

I got an R56 from my R01 application. I am also ESI. You should definitely accept it. It is 1 year plus 1 year renewal (so 2 years total). However, you should spend your money wisely since if your R01 resub is funded, they will cut 1 year (since they already gave your 1 year worth of funding).

Categories: NIH-Funding

Clarifying the Relationship between Delirium and Alzheimers Disease and Related Dementias (R01 Clinical Trial Optional)

NIH Funding Announcements - Mon, 10/30/2017 - 11:43
Funding Opportunity PAR-18-029 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications that focus on clarifying the relationship between delirium and Alzheimer's disease and related dementias (ADRD). Specifically sought is research focusing on understanding why persons with ADRD are at increased risk to develop delirium, often with a worse prognosis compared to those without antecedent ADRD, and why patients who experience delirium are at higher risk to develop subsequent short- and/or long-term mild cognitive impairment or ADRD, often with an accelerated rate of cognitive decline compared to those without preceding delirium. Relevant research projects may focus on, but are not limited to, those that A) provide insight into possible common, sequential, causative, contributory and/or synergistic pathways underlying both ADRD and delirium, B) elucidate mechanisms that lead to the development of delirium against the background of aging and/or neurodegeneration, with particular emphasis on use of appropriate animal models, C) identify risk factors for the onset and/or progression of delirium in those with ADRD and vice versa, D) diagnose and assess one condition in the setting of the other, E) identify putative phenotypes of patients with co-existing ADRD and delirium, or F) test pharmacologic and/or non-pharmacologic strategies to prevent, treat, or reduce the impact of delirium in patients with ADRD and vice versa. Research supported by this FOA is intended to provide mechanistic insight to improve risk assessment, diagnosis, phenotyping, prevention, and management approaches for both delirium and ADRD.
Categories: NIH-Funding

By: Student123

WriteEdit-Grant Questions Blog - Mon, 10/30/2017 - 10:27

Thank you for the reply. What makes this even more complicated is that I’ve recently started at a different institution as a post-doc (different from the institution that I indicated in the F32). I’m itching to talk with my PO about it, but patiently waiting on my summary statement for that. Have you heard of anybody receiving F32 funds who proposed to do their research in a different institution? I know F’s are strongly tied to an institution, unlike K awards which might be more moveable.

Categories: NIH-Funding

Phase III Clinical Trials for the Spectrum of Alzheimer's Disease and Age-related Cognitive Decline (R01 Clinical Trial Required)

NIH Funding Announcements - Mon, 10/30/2017 - 10:24
Funding Opportunity PAR-18-028 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages R01 grant applications that propose to develop and implement Phase III clinical trials of promising pharmacological and non-pharmacological interventions in individuals with age-related cognitive decline and across the Alzheimer's disease (AD) spectrum from pre-symptomatic to more severe stages of disease.
Categories: NIH-Funding

Multidisciplinary Urologic Research (KURe) Career Development Program (K12 Clinical Trial Optional)

NIH Funding Announcements - Mon, 10/30/2017 - 03:02
Funding Opportunity RFA-DK-17-012 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications to support institutional career development programs in urological research that will assist MDs, PhDs, and MD/PhDs with an interest in benign urological disease or urological research to develop the skills necessary to initiate and sustain an independent research career in urological research. Research areas supported by this initiative must be related to the mission of the NIDDK (http://www2.niddk.nih.gov/Research/ScientificAreas/Urology/) This Funding Opportunity Announcement (FOA) allows appointment of Scholars proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary study to an existing trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development.
Categories: NIH-Funding

By: fearless

WriteEdit-Grant Questions Blog - Sun, 10/29/2017 - 12:16

Thank you for your advice.

Categories: NIH-Funding

By: Ruthie

WriteEdit-Grant Questions Blog - Sun, 10/29/2017 - 12:00

Thank you!

Categories: NIH-Funding

By: chemchem

WriteEdit-Grant Questions Blog - Sun, 10/29/2017 - 10:49

Thank you!

Categories: NIH-Funding

By: writedit

WriteEdit-Grant Questions Blog - Sun, 10/29/2017 - 00:02

Paylines should be about the same or slightly better for FY18, depending on what happens in the months ahead. When you receive your summary statement, you can talk with your PO about the likelihood of NIEHS funding the application – either alone or in conjunction with a secondary IC. If the PO has any doubts, you can ask your PO about whether one of the secondary ICs could pick it up (NIEHS PO must relinquish it). If you know the PO at NCI and/or NHLBI, you can also contact them about picking it up (if NIEHS passes) – but first you need to talk with your NIEHS PO with your summary statement in hand. It is not typical for secondary ICs to pick up awards (since they have so many of their own they cannot fund), but it’s not unusual, especially if you have a relationship with a PO at NCI and/or NHLBI and they are interested in your science.

Categories: NIH-Funding

By: writedit

WriteEdit-Grant Questions Blog - Sat, 10/28/2017 - 23:57

Yes – your application has been assigned for review (first to IRG, then SRG), so you should see a date for the study section meeting eventually.

Categories: NIH-Funding

By: writedit

WriteEdit-Grant Questions Blog - Sat, 10/28/2017 - 23:55

The last draft in Congress included $400M for AD and about a $1.1B increase for the NIH overall. This is likely what will ultimately pass, but nothing is final until the President signs the budget into law.

Categories: NIH-Funding

By: writedit

WriteEdit-Grant Questions Blog - Sat, 10/28/2017 - 23:50

The R56 is bridge funding to help you collect additional data toward the resubmission of the R01 (as a new application now). This will not affect your ESI status, and you can apply for the R01 at any time (in case you are running out of time). Assuming the amount of money he is offering will allow you to conduct some of the work proposed in the R01 (and/or collect preliminary data requested or that would address concerns raised by the reviewers), there isn’t a reason not to accept the R56 funding as a bridge to securing the full R01 award.

Categories: NIH-Funding

By: fearless

WriteEdit-Grant Questions Blog - Fri, 10/27/2017 - 21:15

I applied for the NIMH R01 (A1) in March and received 15th percentile in June. I am an ESI. The AC meeting was in September. The PO called me this morning saying that my A1 proposal was unsuccessful. The PO offered R56 for two years instead. Please advise me.

Categories: NIH-Funding

By: Ruthie

WriteEdit-Grant Questions Blog - Fri, 10/27/2017 - 18:58

Does anyone know what the 2018 budget details as far as dollars to NIH and Alzheimer’s disease research?

Categories: NIH-Funding

By: chemchem

WriteEdit-Grant Questions Blog - Fri, 10/27/2017 - 16:03

Dear writedit, I applied for the NIGMS R35 ESI MIRA this month and the status on the eRA commons changed to ‘pending IRG review’ today. Does this mean my application has passed the initial review for responsiveness to NIGMS’s mission?

Categories: NIH-Funding